髓外病变对初诊多发性骨髓瘤患者的影响
回顾性分析上海交通大学医学院附属瑞金医院2015年1月至2022年1月收治的515例初诊多发性骨髓瘤患者,其中114例(22%)伴髓外病变,分为骨旁髓外组91例(18%)和软组织髓外组23例(4%)。结果显示软组织髓外患者预后最差,是总生存的独立危险因素(HR=8.779,P<0.001),自体造血干细胞移植能克服骨旁髓外的不良预后。
要点
- 软组织髓外患者中位无进展生存14.0个月、中位总生存25.6个月,均显著差于非髓外和骨旁髓外患者。
- 软组织髓外是初诊多发性骨髓瘤患者总生存的独立预后危险因素(HR=8.779,P<0.001)。
- 未接受自体造血干细胞移植的骨旁髓外患者总生存显著差于非髓外患者,而接受移植者两组无显著差异。
核心结论
- 与初诊非髓外病变、骨旁髓外病变患者比较,软组织髓外病变患者预后最差,且软组织髓外病变是初诊多发性骨髓瘤患者总生存的独立危险因素。
- 自体造血干细胞移植能克服骨旁髓外病变的不良预后。
研究设计与样本
- 回顾性分析上海交通大学医学院附属瑞金医院2015年1月至2022年1月收治的515例初诊多发性骨髓瘤患者。
- 114例(22%)伴髓外病变,其中骨旁髓外组91例(18%),软组织髓外组23例(4%)。
- 采用卡方检验比较3组临床特征,Kaplan-Meier法比较无进展生存和总生存,Cox比例风险模型多因素分析确定独立预后因素。
主要发现
- 三组患者在年龄、性别、国际分期系统分期、轻链、肌酐清除率、细胞遗传学危险度、17p缺失、是否接受自体造血干细胞移植和诱导方案类型等方面差异均无统计学意义。
- 软组织髓外患者中13%为IgD型M蛋白,显著高于骨旁髓外患者(P=0.021)。
- 非髓外、骨旁髓外和软组织髓外三组中位无进展生存分别为27.4、23.1和14.0个月,中位总生存分别为未达到、76.8个月和25.6个月。
- 软组织髓外患者的无进展生存(对非髓外,P=0.004;对骨旁髓外,P=0.036)和总生存(对非髓外,P<0.001;对骨旁髓外,P=0.002)最差,而骨旁髓外与非髓外组之间无进展生存和总生存差异无统计学意义。
- 在未接受自体造血干细胞移植患者中,骨旁髓外患者总生存显著差于非髓外组(中位76.8个月对未达到,P=0.029);在接受自体造血干细胞移植患者中,骨旁髓外和非髓外组无进展生存和总生存差异无统计学意义。
关键数值与推荐
- 多因素分析中,软组织髓外是初诊多发性骨髓瘤患者总生存的独立预后危险因素(HR=8.779,P<0.001)。
- 软组织髓外对无进展生存也产生不良影响(HR=1.874,P=0.050)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To summarize the characteristics of patients with newly diagnosed multiple myeloma (NDMM) admitted at Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine. We compared the clinical characteristics and prognoses among patients with non-extramedullary disease (EMD), bone-related extramedullary (EM-B) disease, and extraosseous extramedullary (EM-E) disease and further explored the effects of autologous hematopoietic stem cell transplantation (ASCT) for EMD. Methods: From January 2015 to January 2022, data of 114 patients (22%) with EMD out of 515 patients with NDMM were retrospectively analyzed; 91 (18%) and 23 (4%) patients comprised the EM-B and EM-E groups, respectively. The clinical characteristics of patients in all groups were compared with the Chi-square test. Progression-free survival (PFS) and overall survival (OS) of patients were analyzed by the Kaplan-Meier method. Independent prognostic factors were determined using multivariate Cox proportional hazard model. Results: There were no significant differences in age, gender, ISS stage, light chain, creatinine clearance, cytogenetic risk, 17p deletion, ASCT, and induction regimens among the three groups. Overall, 13% of EM-E patients had IgD-type M protein, which was significantly higher than that in EM-B patients (P=0.021). The median PFS of patients in the non-EMD, EM-B, and EM-E groups was 27.4, 23.1, and 14.0 months; the median OS was not reached, 76.8 months, and 25.6 months, respectively. The PFS (vs non-EMD, P=0.004; vs EM-B, P=0.036) and OS (vs non-EMD, P<0.001; vs EM-B, P=0.002) were significantly worse in patients with EM-E, while those were not significantly different between patients with EM-B and those with non-EMD. In the multivariate analysis, EM-E was an independent prognostic factor for OS in patients with NDMM (HR=8.779, P<0.001) and negatively impacted PFS (HR=1.874, P=0.050). In those who did not undergo ASCT, patients with EM-B had significantly worse OS than those with non-EMD (median 76.8 months vs. not reached, P=0.029). However, no significant difference was observed in the PFS and OS of patients with EM-B and those with non-EMD who underwent ASCT. Conclusions: Compared to patients with either non-EMD or EM-B, those with EM-E had the worst prognosis. EM-E was an independent risk factor for OS in patients with NDMM. ASCT can overcome the poor prognosis of EM-B. 目的: 比较初诊多发性骨髓瘤(NDMM)非髓外病变(non-EMD)、骨旁髓外(EM-B)和软组织髓外(EM-E)患者的临床特征及预后,并探讨自体造血干细胞移植(ASCT)对EMD的影响。 方法: 回顾性分析上海交通大学医学院附属瑞金医院2015年1月至2022年1月收治的515例NDMM患者,114例(22%)伴EMD患者,其中EM-B组91例(18%),EM-E组23例(4%)。通过卡方检验比较3组患者临床特征的差异;通过Kaplan-Meier法比较3组患者无进展生存(PFS)和总生存(OS)差异;通过Cox比例风险模型的多因素分析确定独立预后因素。 结果: 三组患者在年龄、性别、国际分期系统(ISS)分期、轻链、肌酐清除率、细胞遗传学危险度、17p缺失、是否接受ASCT和诱导方案类型等方面差异均无统计学意义。13% EM-E患者M蛋白为IgD型,显著增高(P=0.021)。non-EMD、EM-B和EM-E 3组患者中位PFS时间分别为27.4、23.1和14.0个月,中位OS期分别为未达到、76.8个月和25.6个月,EM-E的PFS(对non-EMD,P=0.004;对EM-B,P=0.036)和OS(对non-EMD,P<0.001;对EM-B,P=0.002)最差,而EM-B与non-EMD组之间PFS和OS差异无统计学意义。多因素分析中,EM-E是NDMM患者OS的独立预后危险因素(HR=8.779,P<0.001),对PFS也产生不良影响(HR=1.874,P=0.050)。在未接受ASCT患者中,EM-B患者OS显著差于non-EMD组(中位76.8个月对未达到,P=0.029),但在ASCT患者中,EM-B和non-EMD组PFS和OS差异无统计学意义。 结论: 与初诊non-EMD、EM-B比较,EM-E患者预后最差,而且EM-E是NDMM患者OS的独立危险因素。ASCT能克服EM-B的不良预后。.
引用
- Tao Y, Jin SW, Wang Y, et al. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 36987723. doi:10.3760/cma.j.issn.0253-2727.2023.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。